• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HINFP 作为甾醇调节转录因子 PCSK9 在 HepG2 细胞中的共激活因子的新功能。

The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells.

机构信息

Department of Veterans Affairs, Palo Alto Health Care System, Palo Alto, CA 94304, USA.

出版信息

Biochem J. 2012 May 1;443(3):757-68. doi: 10.1042/BJ20111645.

DOI:10.1042/BJ20111645
PMID:22288532
Abstract

PCSK9 (proprotein convertase subtilisin/kexin type 9) plays an important role in control of plasma LDL (low-density lipoprotein) cholesterol metabolism by modulating the degradation of hepatic LDL receptor. Previous studies demonstrated that PCSK9 is a target gene of the SREBP2 [SRE (sterol-regulatory element)-binding protein 2] that activates PCSK9 gene transcription through an SRE motif of the promoter. In addition to SREBP2, HNF1α (hepatic nuclear factor 1α) positively regulates PCSK9 gene transcription in hepatic cells through a binding site located 28 bp upstream from SRE. In the present study, we have identified a novel HINFP (histone nuclear factor P) recognition motif residing between the HNF1 motif and SRE that is essential for basal and sterol-regulated transcriptions of the PCSK9 promoter. Mutation of this motif lowers the basal promoter activity and abolishes the sterol-mediated repression as well as the SREBP2-induced activation of the PCSK9 promoter. We show further that the activity of SREBP2 in stimulating PCSK9 promoter activity is greatly enhanced by HINFP. Additional experiments suggest that HINFP and its cofactor NPAT (nuclear protein of the ataxia telangectasia mutated locus) form a functional complex, and NPAT may subsequently recruit the HAT (histone acetyltransferase) cofactor TRRAP (transformation/transactivation domain-associated protein) to facilitate the histone H4 acetylation of the PCSK9 promoter. Knockdown of HINFP, NPAT or TRRAP each markedly reduces the amount of acetylated histone H4 on the PCSK9 promoter region and lowers PCSK9 protein levels. Importantly, by utilizing co-immunoprecipitation assays, we have demonstrated a direct interaction between SREBP2 and HINFP and its cofactors NPAT/TRRAP. Taken together, these new findings identify HINFP as a co-activator in SREBP-mediated transactivation of PCSK9 gene expression.

摘要

PCSK9(前蛋白转化酶枯草溶菌素 9)通过调节肝内 LDL 受体的降解,在控制血浆 LDL(低密度脂蛋白)胆固醇代谢中发挥重要作用。先前的研究表明,PCSK9 是 SREBP2 的靶基因,后者通过启动子中的 SRE 基序激活 PCSK9 基因转录。除了 SREBP2 之外,HNF1α(肝核因子 1α)通过位于 SRE 上游 28bp 的结合位点正向调节肝细胞中 PCSK9 基因转录。在本研究中,我们鉴定了一个位于 HNF1 基序和 SRE 之间的新的 HINFP(组蛋白核因子 P)识别基序,该基序对于 PCSK9 启动子的基础转录和固醇调节转录至关重要。该基序的突变降低了基础启动子活性,并消除了固醇介导的抑制以及 SREBP2 诱导的 PCSK9 启动子激活。我们进一步表明,HINFP 极大地增强了 SREBP2 刺激 PCSK9 启动子活性的能力。额外的实验表明,HINFP 及其共因子 NPAT(共济失调毛细血管扩张症突变基因的核蛋白)形成一个功能性复合物,NPAT 随后可能募集 HAT(组蛋白乙酰转移酶)共因子 TRRAP(转化/转导结构域相关蛋白),以促进 PCSK9 启动子的组蛋白 H4 乙酰化。HINFP、NPAT 或 TRRAP 的敲低均显著降低 PCSK9 启动子区域组蛋白 H4 的乙酰化水平,并降低 PCSK9 蛋白水平。重要的是,通过共免疫沉淀测定,我们证明了 SREBP2 与 HINFP 及其共因子 NPAT/TRRAP 之间的直接相互作用。总之,这些新发现确定 HINFP 是 SREBP 介导的 PCSK9 基因表达转录激活的共激活因子。

相似文献

1
The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells.HINFP 作为甾醇调节转录因子 PCSK9 在 HepG2 细胞中的共激活因子的新功能。
Biochem J. 2012 May 1;443(3):757-68. doi: 10.1042/BJ20111645.
2
Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.固醇调节元件结合蛋白-2对前蛋白转化酶枯草杆菌蛋白酶/kexin 9型表达的固醇依赖性调节
J Lipid Res. 2008 Feb;49(2):399-409. doi: 10.1194/jlr.M700443-JLR200. Epub 2007 Oct 5.
3
Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.肝细胞核因子1α在天然降胆固醇化合物小檗碱对前蛋白转化酶枯草溶菌素9(PCSK9)基因的转录和调控中起关键作用。
J Biol Chem. 2009 Oct 16;284(42):28885-95. doi: 10.1074/jbc.M109.052407. Epub 2009 Aug 17.
4
Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.黄连素对前蛋白转化酶枯草溶菌素9(PCSK9)转录的抑制作用涉及通过泛素-蛋白酶体降解途径下调肝脏中肝细胞核因子1α(HNF1α)蛋白的表达。
J Biol Chem. 2015 Feb 13;290(7):4047-58. doi: 10.1074/jbc.M114.597229. Epub 2014 Dec 24.
5
Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.配体和去磷酸化诱导过氧化物酶体增殖物激活受体 γ 的激活,从而诱导蛋白水解酶枯草溶菌素 kexin 9 型和低密度脂蛋白受体的表达。
J Biol Chem. 2012 Jul 6;287(28):23667-77. doi: 10.1074/jbc.M112.350181. Epub 2012 May 16.
6
FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.FoxO3 转录因子和 Sirt6 去乙酰化酶通过控制前蛋白转化酶枯草杆菌蛋白酶/凝血酶 9(Pcsk9)基因的表达来调节低密度脂蛋白(LDL)-胆固醇的稳态。
J Biol Chem. 2013 Oct 11;288(41):29252-9. doi: 10.1074/jbc.M113.481473. Epub 2013 Aug 23.
7
Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.通过 HNF1alpha 和 SREBP2 强烈诱导 PCSK9 基因表达:血脂异常仓鼠他汀类药物降低 LDL 胆固醇作用耐药的机制。
J Lipid Res. 2010 Jun;51(6):1486-95. doi: 10.1194/jlr.M003566. Epub 2010 Jan 4.
8
Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.细胞因子信号转导抑制因子3(SOCS-3)诱导肝癌HepG2细胞系中前蛋白转化酶枯草溶菌素9型(PCSK9)的表达。
J Biol Chem. 2016 Feb 12;291(7):3508-19. doi: 10.1074/jbc.M115.664706. Epub 2015 Dec 14.
9
New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.新型 CETP 抑制剂 K-312 降低 PCSK9 表达:对 LDL 胆固醇代谢的潜在影响。
Am J Physiol Endocrinol Metab. 2015 Jul 15;309(2):E177-90. doi: 10.1152/ajpendo.00528.2014. Epub 2015 May 26.
10
Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.在正常血脂小鼠中,通过肝脏特异性敲低HNF1α降低循环中的PCSK9和LDL-C水平。
J Lipid Res. 2015 Apr;56(4):801-9. doi: 10.1194/jlr.M052969. Epub 2015 Feb 4.

引用本文的文献

1
Regulatory mechanisms of hepatocyte PCSK9 expression: translating mechanistic insights into potential nutraceuticals.肝细胞中前蛋白转化酶枯草溶菌素9(PCSK9)表达的调控机制:将机制性见解转化为潜在的营养保健品
Chin Med. 2025 Aug 5;20(1):121. doi: 10.1186/s13020-025-01178-y.
2
Statins and their impact on epigenetic regulation: insights into disease.他汀类药物及其对表观遗传调控的影响:对疾病的见解
Front Pharmacol. 2025 Jul 17;16:1621163. doi: 10.3389/fphar.2025.1621163. eCollection 2025.
3
The Role of Cholesterol Metabolism and Its Regulation in Tumor Development.
胆固醇代谢及其调节在肿瘤发生中的作用。
Cancer Med. 2025 Apr;14(7):e70783. doi: 10.1002/cam4.70783.
4
Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD-1 Blockade in MSS Colorectal Cancer.甲硫氨酸代谢决定了微卫星稳定型结直肠癌中PCSK9的表达及PD-1阻断的抗肿瘤效力。
Adv Sci (Weinh). 2025 May;12(19):e2501623. doi: 10.1002/advs.202501623. Epub 2025 Mar 24.
5
MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes.微小RNA-99a-5p上调低密度脂蛋白受体,并通过抑制人肝细胞中前蛋白转化酶枯草溶菌素9的表达在功能上增强低密度脂蛋白胆固醇的摄取。
Front Genet. 2024 Nov 19;15:1469094. doi: 10.3389/fgene.2024.1469094. eCollection 2024.
6
New epigenome players in the regulation of PCSK9-H3K4me3 and H3K9ac alterations by statin in hypercholesterolemia.他汀类药物在高胆固醇血症中对PCSK9-H3K4me3和H3K9ac改变调控的新表观基因组作用因子
J Lipid Res. 2025 Jan;66(1):100699. doi: 10.1016/j.jlr.2024.100699. Epub 2024 Nov 19.
7
Deciphering Collagen Phenotype Dynamics Regulators: Insights from In-Silico Analysis.解析胶原蛋白表型动力学调节剂:来自计算机模拟分析的见解
J Bioinform Syst Biol. 2024;7(3):169-181. doi: 10.26502/jbsb.5107089. Epub 2024 Sep 19.
8
Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations.肝外组织中前蛋白转化酶枯草杆菌蛋白酶/kexin 9型缺乏症:新出现的考量因素
Front Pharmacol. 2024 Jul 30;15:1413123. doi: 10.3389/fphar.2024.1413123. eCollection 2024.
9
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.靶向前蛋白转化酶枯草溶菌素 9(PCSK9):从实验室到临床。
Signal Transduct Target Ther. 2024 Jan 8;9(1):13. doi: 10.1038/s41392-023-01690-3.
10
Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation.前蛋白转化酶枯草溶菌素9对动脉粥样硬化性心血管疾病的影响及其机制:聚焦免疫调节
Front Cardiovasc Med. 2023 Mar 10;10:1148486. doi: 10.3389/fcvm.2023.1148486. eCollection 2023.